

## IMPORTANT INFORMATION FOR HEALTHCARE PROFESSIONALS

Page 1/2

**ADCORTYL (triamcinolone acetonide) Intra-articular/Intradermal Injection 10 mg/mL Suspension for Injection, 5mL (PA 0002/018/003)**

### Ireland Notification of Product Shortage

24 April 2024

Dear Healthcare Professional,

Bristol-Myers Squibb Pharmaceuticals (BMS) Unlimited Company regrets to inform you that we are facing a temporary stock shortage of **ADCORTYL (triamcinolone acetonide) Intra-articular/Intradermal Injection 10 mg/mL, 5mL** to the Ireland market. This supply shortage is related to a temporary production issue. It is not related to a safety issue.

We anticipate re-supply of this medicine to resume in the week commencing 20 May 2024, but this is subject to change.

BMS recognises the importance of this medicine and will continue to monitor and seek opportunities to minimise the interruption in supply. We appreciate your patience as we work through this issue.

To help us manage stocks in the coming weeks we would ask that you consider prioritising the ordering of Adcortyl for patients who have the greatest need for this product. This interruption in supply may also require health providers to switch patients to an alternative treatment. These alternatives may have a different efficacy and safety profile and close supervision of the patient by the healthcare provider will be required. For product information on these alternatives, please contact the manufacturers of these products.

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of a medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at: [www.hpra.ie/homepage/about-us/report-an-issue/human-adverse-reaction-form](http://www.hpra.ie/homepage/about-us/report-an-issue/human-adverse-reaction-form). Adverse events should also be reported to Bristol Myers Squibb Medical Information on 1 800 749 749 or [medical.information@bms.com](mailto:medical.information@bms.com).

## Company Contact Point

If you have any further questions or require additional information, please contact BMS Medical Information on 1 800 749 749 or via email at [medical.information@bms.com](mailto:medical.information@bms.com).

Yours Sincerely,

*Hosnieh Fathi*

Hosnieh Fathi (Apr 25, 2024 10:30 GMT+1)

Director - Disease Area Head

Job Code: NO-IE-2400031

Date of preparation: 24 April 2024